<bill session="108" type="h" number="354" updated="2023-01-15T21:19:40Z">
  <state datetime="2003-01-27">REFERRED</state>
  <status>
    <introduced datetime="2003-01-27"/>
  </status>
  <introduced datetime="2003-01-27"/>
  <titles>
    <title type="display">North American Prescription Price Equity Act of 2003</title>
    <title type="official" as="introduced">To amend the Internal Revenue Code of 1986 to allow drug manufacturers a credit against income tax if they certify that the price of a drug in the United States market is not greater than its price in the Canadian or Mexican market.</title>
    <title type="short" as="introduced">North American Prescription Price Equity Act of 2003</title>
  </titles>
  <sponsor bioguide_id="D000533"/>
  <cosponsors/>
  <actions>
    <action datetime="2003-01-27">
      <text>Introduced in House</text>
    </action>
    <action datetime="2003-01-27" state="REFERRED">
      <text>Referred to the House Committee on Ways and Means.</text>
    </action>
  </actions>
  <committees>
    <committee code="HSWM" name="House Ways and Means" subcommittee="" activity="Referral"/>
  </committees>
  <relatedbills/>
  <subjects>
    <term name="Taxation"/>
    <term name="Canada"/>
    <term name="Commerce"/>
    <term name="Drug industry"/>
    <term name="Health"/>
    <term name="Income tax"/>
    <term name="Latin America"/>
    <term name="Mexico"/>
    <term name="Prescription pricing"/>
    <term name="Tax credits"/>
    <term name="Tax deductions"/>
    <term name="Wholesale trade"/>
  </subjects>
  <amendments/>
  <summary date="2006-11-28T17:35:40Z" status="Introduced in House">North American Prescription Price Equity Act of 2003 - Amends the Internal Revenue Code to allow drug manufacturers a limited tax credit if they certify that the wholesale price of a drug in the United States market is not greater than its wholesale price in the Canadian or Mexican market.</summary>
</bill>
